Online inquiry

IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3096MR)

This product GTTS-WQ3096MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FASLG gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 356
UniProt ID Q53ZZ1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ3096MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13625MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ14795MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ9179MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ848MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ4373MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ2489MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ4459MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ11063MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCLA-158
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW